HSV-2 Vaccine: Current Status and Insight into Factors for Developing an Efficient Vaccine

被引:34
|
作者
Zhu, Xiao-Peng [1 ]
Muhammad, Zaka S. [2 ]
Wang, Jian-Guang [3 ]
Lin, Wu [1 ]
Guo, Shi-Kun [1 ]
Zhang, Wei [3 ]
机构
[1] Wenzhou Med Univ, Clin Med Coll 2, Wenzhou 325025, Zhejiang, Peoples R China
[2] Wenzhou Med Univ, Sch Int Studies, Wenzhou 325025, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Sch Basic Med Sci, Wenzhou 325025, Zhejiang, Peoples R China
来源
VIRUSES-BASEL | 2014年 / 6卷 / 02期
关键词
herpes simplex virus 2; vaccine; mucosal immunity; delivery route; adjuvant; sex hormone; HERPES-SIMPLEX-VIRUS; FEMALE GENITAL-TRACT; PLASMACYTOID DENDRITIC CELLS; RAPIDLY CLEARED EPISODES; PLASMID DNA VACCINE; GLYCOPROTEIN-D; PROTECTIVE IMMUNITY; SUBCUTANEOUS IMMUNIZATION; VIRAL-INFECTIONS; MUCOSAL ADJUVANT;
D O I
10.3390/v6020371
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Herpes simplex virus type 2 (HSV-2), a globally sexually transmitted virus, and also one of the main causes of genital ulcer diseases, increases susceptibility to HIV-1. Effective vaccines to prevent HSV-2 infection are not yet available, but are currently being developed. To facilitate this process, the latest progress in development of these vaccines is reviewed in this paper. A summary of the most promising HSV-2 vaccines tested in animals in the last five years is presented, including the main factors, and new ideas for developing an effective vaccine from animal experiments and human clinical trials. Experimental results indicate that future HSV-2 vaccines may depend on a strategy that targets mucosal immunity. Furthermore, estradiol, which increases the effectiveness of vaccines, may be considered as an adjuvant. Therefore, this review is expected to provide possible strategies for development of future HSV-2 vaccines.
引用
收藏
页码:371 / 390
页数:20
相关论文
共 50 条
  • [1] HSV-2: in pursuit of a vaccine
    Johnston, Christine
    Koelle, David M.
    Wald, Anna
    JOURNAL OF CLINICAL INVESTIGATION, 2011, 121 (12): : 4600 - 4609
  • [2] Development of a therapeutic vaccine for HSV-2
    Hosken, NA
    VACCINE, 2005, 23 (17-18) : 2395 - 2398
  • [3] HSV-2 vaccine: Current state and insights into development of a vaccine that targets genital mucosal protection
    Roth, Kristy
    Ferreira, Victor H.
    Kaushic, Charu
    MICROBIAL PATHOGENESIS, 2013, 58 : 45 - 54
  • [4] Dynamics of HSV-2 infection with a therapeutic vaccine
    Venturino, Ezio
    Shoukat, Affan
    Moghadas, Seyed M.
    HELIYON, 2020, 6 (07)
  • [5] Current status and prospects for development of an HSV vaccine
    Johnston, Christine
    Koelle, David M.
    Wald, Anna
    VACCINE, 2014, 32 (14) : 1553 - 1560
  • [6] Vical initiates vaccine trials against HSV-2 and CMV
    Riedmann, Eva M.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (02) : 255 - 255
  • [7] Stabilization of HSV-2 viral vaccine candidate by spray drying
    LeClair, Daniel A.
    Li, Lillian
    Rahman, Nausheen
    Cranston, Emily D.
    Xing, Zhou
    Thompson, Michael R.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2019, 569
  • [8] Review of mathematical models of HSV-2 vaccination: Implications for vaccine development
    Spicknall, Ian H.
    Looker, Katharine J.
    Gottlieb, Sami L.
    Chesson, Harrell W.
    Schiffer, Joshua T.
    Elmes, Jocelyn
    Boily, Marie-Claude
    VACCINE, 2019, 37 (50) : 7396 - 7407
  • [9] A Herpes Simplex Virus 2 (HSV-2) Glycoprotein D-expressing Nonreplicating Dominant-Negative HSV-2 Virus Vaccine Is Superior to a gD2 Subunit Vaccine against HSV-2 Genital Infection in Guinea Pigs
    Zhang, Pengwei
    Xie, Lining
    Balliet, John W.
    Casimiro, Danilo R.
    Yao, Feng
    PLOS ONE, 2014, 9 (06):
  • [10] A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2
    Wang, Kening
    Goodman, Kyle N.
    Li, Daniel Y.
    Raffeld, Mark
    Chavez, Mayra
    Cohen, Jeffrey I.
    JOURNAL OF VIROLOGY, 2016, 90 (01) : 562 - 574